ReviewMolecular biology reports2023
Fucose-binding lectins: purification, characterization and potential biomedical applications.
Review in Molecular biology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- L-Fucose: a dietary sugar with multifaceted potential in the biology and therapy of cancer.Nature reviews. Cancer · 2026Review
- Quorum Sensing inMicroorganisms · 2025Article
- Development of serum glycosylated exosomal microRNAs as biomarkers for early diagnosis of lung adenocarcinoma.Frontiers in medicine · 2025Article
- Nano-bio-encapsulation of phyto-vaccines: a breakthrough in targeted cancer immunotherapy.Molecular biology reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The property of lectins to specifically recognize and bind carbohydrates makes them an excellent candidate in biomedical research. Among them are fucose-binding lectins possessing the capacity to bind fucose are taxonomically, evolutionarily and ecologically significant class of lectins that are identified in a wide range of taxa. Purification of fucose-binding lectins dates back to 1967 when L-fucose binding protein from Lotus tetragonolobus was isolated using a dye that contained three α-L-fucopyranosyl residues. Beginning with that, several FBLs were purified from various animals as well as plant sources that were structurally and functionally characterised. This review focuses on fucose-binding lectins, their occurrence and purification with special emphasis on various strategies adopted to purify them followed by molecular and functional characterization. The exclusive ability to recognize and bind to fucose-containing glycans endows these lectins with the potential to act as anti-cancer agents, diagnostic markers and mitogens for immune cells. Though they have been in research focus for more than half a century with their occurrence reported in various taxa, they still need to be explored for their prospective functions to develop them as a biological tool in biomedical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.